Literature DB >> 17079873

An alternatively spliced form of Met receptor is tumorigenic.

Jae-Ho Lee1, Chong Feng Gao, Chong Chou Lee, Myung Deok Kim, George F Vande Woude.   

Abstract

The Met tyrosine kinase receptor is a widely expressed molecule, which mediates pleiotropic cellular responses following activation by its ligand, hepatocyte growth factor/scatter factor (HGF/SF). Previously, one of the authors identified an alternatively spliced form of Met (Met-SM) that lacked a single exon of a 47-amino-acid segment in the juxtamembrane domain. Here we report that Met-SM is a potent transforming gene in NIH3T3 mouse fibroblast cells. Met-SM-transfected NIH3T3 cells show stronger foci-forming activity than wild type- Met-transfected ones. In addition, Met-SM-transfected NIH3T3 cells form colonies in soft agar and are tumorigenic in athymic nu/nu mice. Furthermore, HGF/SF significantly increases the focus-forming activity of Met-SM comparing to wild type Met. The amount of protein and of tyrosine kinase activity of Met-SM accumulates to a high level following HGF/SF treatment. The accumulation of Met-SM correlated well with its delayed ubiquitination and increased stability. These results are consistent with the important role of the juxtamembrane domain in protein stability of Met receptor and suggest that the alternatively-spliced form may contribute to the development and progression of human cancer.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17079873     DOI: 10.1038/emm.2006.66

Source DB:  PubMed          Journal:  Exp Mol Med        ISSN: 1226-3613            Impact factor:   8.718


  18 in total

Review 1.  MET exon 14 juxtamembrane splicing mutations: clinical and therapeutical perspectives for cancer therapy.

Authors:  Sara Pilotto; Anastasios Gkountakos; Luisa Carbognin; Aldo Scarpa; Giampaolo Tortora; Emilio Bria
Journal:  Ann Transl Med       Date:  2017-01

Review 2.  The role of RNA alternative splicing in regulating cancer metabolism.

Authors:  Itamar Kozlovski; Zahava Siegfried; Adi Amar-Schwartz; Rotem Karni
Journal:  Hum Genet       Date:  2017-04-20       Impact factor: 4.132

3.  Cancer genes in lung cancer: racial disparities: are there any?

Authors:  Ahmed El-Telbany; Patrick C Ma
Journal:  Genes Cancer       Date:  2012-07

Review 4.  Function of alternative splicing.

Authors:  Olga Kelemen; Paolo Convertini; Zhaiyi Zhang; Yuan Wen; Manli Shen; Marina Falaleeva; Stefan Stamm
Journal:  Gene       Date:  2012-08-15       Impact factor: 3.688

5.  MET Genomic Alterations in Head and Neck Squamous Cell Carcinoma (HNSCC): Rapid Response to Crizotinib in a Patient with HNSCC with a Novel MET R1004G Mutation.

Authors:  Lisa Pei Chu; Debra Franck; Christine A Parachoniak; Jeffrey P Gregg; Michael G Moore; D Gregory Farwell; Shyam Rao; Andreas M Heilmann; Rachel L Erlich; Jeffrey S Ross; Vincent A Miller; Siraj Ali; Jonathan W Riess
Journal:  Oncologist       Date:  2019-08-07

6.  A novel isoform of met receptor tyrosine kinase blocks hepatocyte growth factor/Met signaling and stimulates skeletal muscle cell differentiation.

Authors:  Minseon Park; Bok-Soon Lee; Soung-Hoo Jeon; Hyun-Ja Nam; Gwang Lee; Chul-Ho Kim; Hyeseong Cho; Jae-Ho Lee
Journal:  J Biol Chem       Date:  2014-12-03       Impact factor: 5.157

7.  The angiotensin IV analog Nle-Tyr-Leu-psi-(CH2-NH2)3-4-His-Pro-Phe (norleual) can act as a hepatocyte growth factor/c-Met inhibitor.

Authors:  B J Yamamoto; P D Elias; J A Masino; B D Hudson; A T McCoy; Z J Anderson; M D Varnum; M F Sardinia; J W Wright; J W Harding
Journal:  J Pharmacol Exp Ther       Date:  2010-01-19       Impact factor: 4.030

8.  Mutations Preventing Regulated Exon Skipping in MET Cause Osteofibrous Dysplasia.

Authors:  Mary J Gray; Peter Kannu; Swarkar Sharma; Christine Neyt; Dongping Zhang; Nandina Paria; Philip B Daniel; Heather Whetstone; Hans-Georg Sprenger; Philipp Hammerschmidt; Angela Weng; Lucie Dupuis; Rebekah Jobling; Roberto Mendoza-Londono; Michael Dray; Peiqiang Su; Megan J Wilson; Raj P Kapur; Edward F McCarthy; Benjamin A Alman; Andrew Howard; Gino R Somers; Christian R Marshall; Simon Manners; Adrienne M Flanagan; Karl E Rathjen; Lori A Karol; Haemish Crawford; David M Markie; Jonathan J Rios; Carol A Wise; Stephen P Robertson
Journal:  Am J Hum Genet       Date:  2015-12-03       Impact factor: 11.025

9.  Alternative splicing in oncogenic kinases: from physiological functions to cancer.

Authors:  Sabine Druillennec; Coralie Dorard; Alain Eychène
Journal:  J Nucleic Acids       Date:  2011-10-05

10.  Alternative splicing and tumor progression.

Authors:  Claudia Ghigna; Cristina Valacca; Giuseppe Biamonti
Journal:  Curr Genomics       Date:  2008-12       Impact factor: 2.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.